US 12,365,738 B2
Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibody
Robert A. Horlick, San Diego, CA (US); Helen Toni Jun, San Diego, CA (US); and David J. King, Encinitas, CA (US)
Assigned to Lassen Therapeutics, Inc., San Diego, CA (US)
Filed by Lassen Therapeutics, Inc., San Diego, CA (US)
Filed on Sep. 25, 2024, as Appl. No. 18/896,799.
Application 18/896,799 is a division of application No. 18/590,853, filed on Feb. 28, 2024, granted, now 12,129,303.
Application 18/590,853 is a continuation of application No. PCT/US2022/075680, filed on Aug. 30, 2022.
Claims priority of provisional application 63/334,923, filed on Apr. 26, 2022.
Claims priority of provisional application 63/238,443, filed on Aug. 30, 2021.
Prior Publication US 2025/0011444 A1, Jan. 9, 2025
Int. Cl. C07K 16/28 (2006.01); A61P 11/00 (2006.01); A61P 43/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 11/00 (2018.01); A61P 43/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A method of treating an IL-11-associated or IL-11-mediated fibrotic disease or condition in a subject in need thereof, comprising administering to the subject an antibody, or antigen binding fragment thereof, which binds to interleukin-11 receptor subunit α (IL-11Rα), wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences and the VL comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences, and wherein:
a. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 25-27, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 28-30, respectively;
b. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 91-93, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 94-96, respectively;
c. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 97-99, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 100-102, respectively;
d. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 103-105, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 106-108, respectively;
e. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 109-111, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 112-114, respectively;
f. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 115-117, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 118-120, respectively;
g. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 121-123, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 124-126, respectively;
h. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 127-129, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 130-132, respectively;
i. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 133-135, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 136-138, respectively;
j. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 139-141, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 142-144, respectively;
k. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 145-147, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 148-150, respectively;
l. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 151-153, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 154-156, respectively;
m. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 157-159, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 160-162, respectively;
n. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 163-165, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 166-168, respectively;
o. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 169-171, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 172-174, respectively;
p. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 175-177, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 178-180, respectively;
q. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 181-183, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 184-186, respectively; or
r. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 187-189, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 190-192, respectively.